Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Opinion CV Team Dispatch

October 2021 News Roundup

L.A. McKeown

October 01, 2021

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Conference News HFSA 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Michael O'Riordan

September 14, 2021

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Todd Neale

September 13, 2021

News Daily News

Biomarker Levels ID Patients With Most to Gain From Intensive BP Lowering

Todd Neale

September 08, 2021

News Opinion CV Team Dispatch

September 2021 News Roundup

L.A. McKeown

September 01, 2021

News Opinion CV Team Dispatch

July/August 2021 News Roundup

L.A. McKeown

August 01, 2021

News Daily News

ARBs Preferable to ACE Inhibitors in Large Observational Hypertension Study

Michael O'Riordan

July 27, 2021

News Daily News

Making the Case for Sex-Specific CVD Guidelines

L.A. McKeown

July 08, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Opinion CV Team Dispatch

April 2021 News Roundup

L.A. McKeown

April 10, 2021

Advertisement

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Canagliflozin Improves Quality of Life in HF Patients

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 2021 News Roundup

October 2021 News Roundup

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Biomarker Levels ID Patients With Most to Gain From Intensive BP Lowering

September 2021 News Roundup

July/August 2021 News Roundup

ARBs Preferable to ACE Inhibitors in Large Observational Hypertension Study

Making the Case for Sex-Specific CVD Guidelines

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Less Cancer Among HF Patients Taking Statins, Registry Shows

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

FDA Approves Dapagliflozin for CKD Patients

April 2021 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content